Camrelizumab plus famitinib as first-line treatment in advanced NSCLC patients with PD-L1 TPS ≥1%: A report from a multicenter, open-label, phase II basket trial

被引：0
|
作者：
Ren, S. [1 ]
Wang, X. [2 ]
Han, B. [3 ]
Pan, Y. [4 ]
Zhao, J. [5 ]
Cheng, Y. [6 ,10 ]
Hu, S. [7 ]
Liu, T. [8 ]
Li, Y. [9 ]
Cheng, Y. [6 ,10 ]
Feng, J. [11 ]
Yi, S. [12 ]
Gu, S. [13 ]
Gao, S. [14 ]
Luo, Y. [15 ,16 ]
Liu, Y. [17 ]
Liu, C. [18 ]
Duan, H. [19 ]
Zhou, C. [1 ]
Fan, J. [20 ]
机构：
[1] Shanghai Pulm Hosp, Oncol Dept, Shanghai, Peoples R China
[2] Guangdong Pharmaceut Univ, Dept Oncol, Affiliated Hosp 1, Guangzhou, Peoples R China
[3] Shanghai Chest Hosp, Dept Resp, Shanghai, Peoples R China
[4] USTC, Oncol Chemotherapy Dept, Affiliated Hosp 1, Anhui Prov Hosp, Hefei, Peoples R China
[5] Beijing Canc Hosp, Dept Thorac Med Oncol, Beijing, Peoples R China
[6] Shandong Univ, Dept Chemotherapy, Qilu Hosp, Jinan, Peoples R China
[7] Hubei Canc Hosp, Dept Thorac Tumor, Wuhan, Peoples R China
[8] Fudan Univ, Dept Med Oncol, Med Oncol Dept, Zhongshan Hosp, Shanghai, Peoples R China
[9] Sichuan Univ, Resp & Crit Care Med, West China Hosp, West China Sch Med, Chengdu, Peoples R China
[10] Jilin Canc Hosp, Dept Med Oncol, Changchun, Peoples R China
[11] Nanjing Med Univ, Jiangsu Inst Canc Res, Jiangsu Canc Hosp, Dept Med Oncol,Affiliated Canc Hosp, Nanjing, Peoples R China
[12] Zhengzhou Cent Hosp, Dept Med Oncol, Zhengzhou, Peoples R China
[13] Hunan Canc Hosp, Dept Intervent Radiol, Changsha, Peoples R China
[14] Henan Univ Sci & Technol, Dept Med Oncol, Affiliated Hosp 1, Luoyang, Peoples R China
[15] Cent South Univ, Thorac Med Dept, Hunan Canc Hosp, Changsha, Peoples R China
[16] Cent South Univ, Affiliated Canc Hosp, Xiangya Sch Med, Changsha, Peoples R China
[17] Zhengzhou Univ, Henan Canc Hosp, Dept Gastroenterol, Affiliated Canc Hosp, Zhengzhou, Peoples R China
[18] China Med Univ, Dept Oncol, Shengjing Hosp, Shenyang, Peoples R China
[19] Jiangsu Hengrui Pharmaceut Co Ltd, Clin Res & Dev, Shanghai, Peoples R China
[20] Fudan Univ, Zhongshan Hosp, Dept Liver Surg & Transplantat, Shanghai, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
43P
引用
收藏
页码：S66 / S67
页数：2
相关论文
共 50 条
  • [21] Osimertinib Plus Durvalumab in Patients With EGFR-Mutated, Advanced NSCLC: A Phase 1b, Open-Label, Multicenter Trial
    Ahn, Myung-Ju
    Cho, Byoung Chul
    Ou, Xiaoling
    Walding, Andrew
    Dymond, Angela W.
    Ren, Song
    Cantarini, Mireille
    Janne, Pasi A.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (05) : 718 - 723
  • [22] FoRT 05-BEAT: A phase II randomized trial comparing atezolizumab versus atezolizumab plus bevacizumab as first-line treatment in patients with PD-L1 high advanced/metastatic NSCLC.
    Migliorino, Rita
    Landi, Lorenza
    Galetta, Domenico
    Soregaroli, Daniela
    Ricciardi, Serena
    Minuti, Gabriele
    Montrone, Michele
    Marech, Ilaria
    Morabito, Alessandro
    Berardi, Rossana
    Novello, Silvia
    Rocco, Danilo
    Pilotto, Sara
    Zanelli, Francesca
    Bengala, Carmelo
    Delmonte, Angelo
    Aieta, Michele
    Cortinovis, Diego Luigi
    Cappuzzo, Federico
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [23] Update results of anlotinib combined with TQB2450 (PD-L1 blockade) as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, multicenter, open-label phase II clinical trial
    Hong, G.
    Meng, X.
    Yang, X.
    Zhang, Z. Y.
    Xia, J.
    Chen, Y-F.
    Wu, T.
    Shan, Z.
    Fan, Q.
    Wang, F.
    ANNALS OF ONCOLOGY, 2023, 34 : S861 - S861
  • [24] First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial
    Paz-Ares, Luis G.
    Ramalingam, Suresh S.
    Ciuleanu, Tudor-Eliade
    Lee, Jong-Seok
    Urban, Laszlo
    Caro, Reyes Bernabe
    Park, Keunchil
    Sakai, Hiroshi
    Ohe, Yuichiro
    Nishio, Makoto
    Audigier-Valette, Clarisse
    Burgers, Jacobus A.
    Pluzanski, Adam
    Sangha, Randeep
    Gallardo, Carlos
    Takeda, Masayuki
    Linardou, Helena
    Lupinacci, Lorena
    Lee, Ki Hyeong
    Caserta, Claudia
    Provencio, Mariano
    Carcereny, Enric
    Otterson, Gregory A.
    Schenker, Michael
    Zurawski, Bogdan
    Alexandru, Aurelia
    Vergnenegre, Alain
    Raimbourg, Judith
    Feeney, Kynan
    Kim, Sang-We
    Borghaei, Hossein
    O'Byrne, Kenneth John
    Hellmann, Matthew D.
    Memaj, Arteid
    Nathan, Faith Ellen
    Bushong, Judith
    Phuong Tran
    Brahmer, Julie R.
    Reck, Martin
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (02) : 289 - 308
  • [25] Anlotinib plus TQB2450 (PD-L1 blockade) combined with nab-paclitaxel and cisplatin as first-line treatment for advanced biliary tract cancer: A single-arm, open-label phase II clinical trial
    Jin, Shui-Ling
    Qiao, Shishi
    Li, Ren-Feng
    Zhang, Weijie
    He, Wei
    Su, Chang
    Li, Lu-Hao
    Pan, Jie
    Guo, Wen-Zhi
    Zong, Hong
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 498 - 498
  • [26] Anti-PD-1/PD-L1 plus chemotherapy versus chemotherapy alone in first-line treatment for patients with metastatic NSCLC that were PD-L1 negative or less than 1%.
    Landre, Thierry
    Guetz, Gaetan Des
    Chouahnia, Kader
    Taleb, Cherifa
    Vergnenegre, Alain
    Chouaid, Christos
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [27] Efficacy of Tiragolumab plus Atezolizumab in PD-L1 IHC and TIGIT Subgroups in the Phase II CITYSCAPE Study in First-Line NSCLC
    Patil, N.
    Cho, B. C.
    Johnson, M.
    Caro, R. B.
    Spira, A.
    Chiu, C.
    Molden, N.
    Pham, T.
    Yang, X.
    Choi, Y.
    Zhang, Z.
    Hoang, T.
    Ballinger, M.
    Meng, R.
    Rodriguez-Abreu, D.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S635 - S636
  • [28] The overall survival data of FUTURE-C-PLUS: Combination of famitinib with camrelizumab plus nab-paclitaxel as first-line treatment for advanced, immunomodulatory triple-negative breast cancer, an open-label, single-arm, phase II trial
    Wang, Z.
    Chen, L.
    Fan, L.
    Shao, Z.
    ANNALS OF ONCOLOGY, 2023, 34 : S361 - S361
  • [29] Camrelizumab (C) in combination with apatinib (A) in patients with advanced hepatocellular carcinoma (RESCUE): An open-label, multicenter, phase II trial
    Xu, J.
    Shen, J.
    Gu, S.
    Zhang, Y.
    Wu, L.
    Wu, J.
    Shao, G.
    Zhang, Y.
    Xu, L.
    Yin, T.
    Liu, J.
    Ren, Z.
    Xiong, J.
    Mao, X.
    Zhang, L.
    Yang, J.
    Li, L.
    Chen, X.
    Wang, Z.
    Wang, Q.
    ANNALS OF ONCOLOGY, 2020, 31 : S689 - S689
  • [30] Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 1%: Open-label, phase 3 KEYNOTE-042 study.
    Lopes, Gilberto
    Wu, Yi-Long
    Kudaba, Iveta
    Kowalski, Dariusz
    Cho, Byoung Chul
    Castro, Gilberto
    Srimuninnimit, Vichien
    Bondarenko, Igor
    Kubota, Kaoru
    Lubiniecki, Gregory M.
    Zhang, Jin
    Kush, Debra A.
    Mok, Tony
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (18)
12345